



an **ACCURAY** reference site

# Accuray Disclaimers and Disclosure

## **Disclosure**

The views contained and expressed in this presentation, including any accompanying oral commentary, are those of the presenter and do not necessarily reflect the views or policies of Accuray Incorporated or its subsidiaries. No official endorsement by Accuray Incorporated or any of its subsidiaries of any vendor, products or services contained in this presentation is intended or should be inferred.

An honorarium is provided by Accuray for this presentation.

## **Medical Advice Disclaimer**

Accuray Incorporated as a medical device manufacturer cannot and does not recommend specific treatment approaches. Individual results may vary.

## **Safety Statement**

Most side effects of radiotherapy, including radiotherapy delivered with Accuray systems, are mild and temporary, often involving fatigue, nausea, and skin irritation. Side effects can be severe, however, leading to pain, alterations in normal body functions (for example, urinary or salivary function), deterioration of quality of life, permanent injury and even death. Side effects can occur during or shortly after radiation treatment or in the months and years following radiation. The nature and severity of side effects depend on many factors, including the size and location of the treated tumor, the treatment technique (for example, the radiation dose), the patient's general medical condition, to name a few. For more details about the side effects of your radiation therapy, and if treatment with an Accuray product is right for you, ask your doctor.

# About CARTI

- Founded in 1976
- Arkansas' largest oncology care provider
- Treat adult cancers & blood disorders
- Treat approx. 50k patients annually
- CARTI believes treatment should be provided to patients close to home
- Statewide network of cancer care providers & treatment locations:
  - 19 locations; 16 communities
  - 6 Radiation Oncology sites




# The CARTI Radiation Oncology Team



- 9 Radiation Oncologists
- 2 Physician Assistants
- 9 Medical Physicists
- 3 Physics Residents
- 1 Physics Assistant
- 10 Medical Dosimetrists
- 1 Dosimetry Student
- 34 Radiation Therapists
- 5 Radiation Therapy Students
- 12 Radiation Oncology Nurses
- 13 Patient Support Specialists

# Radiation Oncology

- We treat ~3,800 unique pts/yr
- Perform ~9,500 Consults/FU
- Treatment modalities
  - SRS (approx. 450 pts/yr)
  - SBRT (approx. 750 pts/yr)
  - HDR (approx. 30 pts/yr)
- Treated **346** unique pts w/ CyberKnife Year 1, **445** unique pts Year 2. On pace to treat ~**500** unique CyberKnife pts in Year 3.



# So Why a CyberKnife System for CARTI?

1. Either meets an unmet need or allows us to better meet an existing need
2. Provide differentiating value for our patients and care team
3. Capacity / Throughput
4. Dedicated SRS/SBRT Machine
5. MUST be Scalable
6. Potential for Adaptive Treatment Delivery
7. Positive Financial Analysis / Breakeven Analysis / ROI



# Meets an unmet need OR better meets an existing need

## Areas of opportunity include:


- **Intracranial, Prostate, Lung, Intraabdominal, Spine, & Non-oncologic conditions**
- Robust neurosurgical relationship
- Precise, robotic treatment for lesions anywhere in the body
- Accurately treat stationary targets or targets in motion
- Increased confidence with sub-millimeter robotic accuracy
- Functional disease: acoustic neuroma, schwannoma, pituitary adenoma, hemangioblastoma, craniopharngioma, arteriovenous malformation, cavernous malformation and trigeminal neuralgia




# Capacity / Throughput

**Our Goal:** ~6pts/day Yr. 1; ~15 pts/day by Yr. 7\*

\*~380 pts/year Yr. 1; ~ 950 pts/year by Yr. 7




Annual Patients Treated






# Support Every Step of the Way

<b>Construction</b>	<b>Virtual Training</b>	<b>Remote In-Person Training</b>	<b>On-site Pre-GO LIVE Support</b>	<b>Pre Launch Marketing</b>	<b>On-site GO LIVE Support</b>	<b>Post Launch Marketing</b>	<b>Post Launch Training</b>	<b>Refresher/ NEW Team Member Training</b>
Project Manager, Architect, Contractor	RadOncs, Physics, & Dosimetry	Physics & Radiation Therapists	Physics Dosimetry, & Radiation Therapists	Referring Providers, Local & Regional Press, Local Organizations, & Direct to Patient	RadOncs, Physics, Dosimetry, & Radiation Therapy	Referring Providers, Local & Regional Press, Local Organizations, & Direct to Patient	Physics, Dosimetry, & Radiation Therapists	RadOncs, Physicists, Dosimetrists, & Radiation Therapists




# Present State of CyberKnife System at CARTI

- Predict treating 500 pts in 2024
  - ~6pts/day average
- Currently treat the following:
  - Primary Brain
  - Singular Brain Mets
  - Multiple Brain Mets
  - Lung w/o fiducials
  - Spine
  - Liver w/ fiducials
  - Prostate w/ fiducials



# Looking to the Future

- Continue to develop & cultivate neurosurgical engagement
  - Continue to grow our direct to patient prostate volume
    - Explore potential for SBRT and/or APBI Breast Utility
    - Increase non-fiducial based SBRT Lung Utilization
    - Expand non-oncologic treatment indications
  - Consider additional functional disease





**Questions?**



# Contact Info

**Jeremy Land MBA, CMD, BSRT(T)(CT)(R)(QM)**  
SVP of Regional Operations  
[Jeremy.Land@CARTI.com](mailto:Jeremy.Land@CARTI.com)  
1+(501)296-3233



+





CARTI

an **ACCURAY** reference site